Literature DB >> 7688956

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.

M Q Xia1, G Hale, M R Lifely, M A Ferguson, D Campbell, L Packman, H Waldmann.   

Abstract

CAMPATH-1 antibodies recognize a unique molecule on human lymphocytes and are unusually efficient at causing cell lysis with homologous complement. They have been successfully used for lymphocyte depletion in vivo in a variety of diseases. We find that the antigen is a very small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids. It can be separated into two distinct antigenic fractions which differ in their susceptibility to phosphatidylinositol-specific phospholipase C. There is one N-linked glycosylation site, but no evidence for O-glycosylation despite the presence of several serine and threonine residues. The antibodies were found to bind, albeit with a generally reduced affinity, to a proteolytic fragment containing the C-terminal tripeptide and the GPI anchor. We postulate that one of the reasons why the CAMPATH-1 antibodies are so good for cell lysis is because they bind to an epitope which is likely to be very close to the lipid bilayer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688956      PMCID: PMC1134413          DOI: 10.1042/bj2930633

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  45 in total

1.  Therapeutic potential of monoclonal antibodies to the leukocyte-common antigen. Synergy and interference in complement-mediated lysis.

Authors:  C I Bindon; G Hale; M Clark; H Waldmann
Journal:  Transplantation       Date:  1985-11       Impact factor: 4.939

2.  Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow.

Authors:  U M Saarinen; P F Coccia; S L Gerson; R Pelley; N K Cheung
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Enzyme amplification--a general method applied to provide an immunoassisted assay for placental alkaline phosphatase.

Authors:  C H Self
Journal:  J Immunol Methods       Date:  1985-02-11       Impact factor: 2.303

5.  Phase separation of integral membrane proteins in Triton X-114 solution.

Authors:  C Bordier
Journal:  J Biol Chem       Date:  1981-02-25       Impact factor: 5.157

6.  Proline-specific endopeptidase from Flavobacterium. Purification and properties.

Authors:  T Yoshimoto; R Walter; D Tsuru
Journal:  J Biol Chem       Date:  1980-05-25       Impact factor: 5.157

7.  Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung.

Authors:  M Mabry; J A Speak; J D Griffin; R A Stahel; S D Bernal
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

8.  Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.

Authors:  I Hellström; P L Beaumier; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

9.  Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement.

Authors:  G Hale; S Bright; G Chumbley; T Hoang; D Metcalf; A J Munro; H Waldmann
Journal:  Blood       Date:  1983-10       Impact factor: 22.113

10.  Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.

Authors:  A N Houghton; D Mintzer; C Cordon-Cardo; S Welt; B Fliegel; S Vadhan; E Carswell; M R Melamed; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

View more
  50 in total

1.  Recognition of CD52 allelic gene products by CAMPATH-1H antibodies.

Authors:  C Hale; M Bartholomew; V Taylor; J Stables; P Topley; J Tite
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

2.  Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.

Authors:  Kirstie L S Cleary; H T Claude Chan; Sonja James; Martin J Glennie; Mark S Cragg
Journal:  J Immunol       Date:  2017-04-12       Impact factor: 5.422

Review 3.  Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.

Authors:  Carsten Denkert; Silvia Darb-Esfahani; Sibylle Loibl; Ioannis Anagnostopoulos; Korinna Jöhrens
Journal:  Semin Immunopathol       Date:  2011-04-17       Impact factor: 9.623

Review 4.  Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  Xu Zhang; Raymond Hupperts; Marc De Baets
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

5.  Regulation unmasked by activation.

Authors:  Mike Clark; Anne Cooke
Journal:  Nat Immunol       Date:  2013-07       Impact factor: 25.606

6.  CD52 as both a marker and an effector molecule of T cells with regulatory action: Identification of novel regulatory T cells.

Authors:  Buka Samten
Journal:  Cell Mol Immunol       Date:  2013-09-16       Impact factor: 11.530

7.  Efficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing role.

Authors:  Christina Caon; Cathy Meyer; Lori Mayer; M Shelton Smith
Journal:  Int J MS Care       Date:  2013

Review 8.  Immune mechanisms underlying the beneficial effects of autologous hematopoietic stem cell transplantation in multiple sclerosis.

Authors:  David Gosselin; Serge Rivest
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

9.  Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.

Authors:  Liuyan Jiang; Constance M Yuan; Julia Hubacheck; John E Janik; Wyndham Wilson; John C Morris; Gregory A Jasper; Maryalice Stetler-Stevenson
Journal:  Br J Haematol       Date:  2009-02-19       Impact factor: 6.998

10.  Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.

Authors:  W Rowan; J Tite; P Topley; S J Brett
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.